[1]
|
Mollaeian, A. and Haas, C. (2020) A Tale of Autoimmunity: Thymoma, Thymectomy, and Systemic Lupus Erythemato-sus. Clinical Rheumatology, 39, 2227-2234. https://doi.org/10.1007/s10067-020-05061-z
|
[2]
|
Xu, C., Zhang, Y., Wang, W., et al. (2023) Chinese Expert Consensus on the Diagnosis and Treatment of Thymic Epithelial Tumors. Tho-racic Cancer, 14, 1102-1117. https://doi.org/10.1111/1759-7714.14847
|
[3]
|
中国医师协会肿瘤多学科诊疗专业委员会. 中国胸腺上皮肿瘤临床诊疗指南(2021版) [J]. 中华肿瘤杂志, 2021, 43(4): 395-404.
|
[4]
|
王琳琳, 邹文远, 石思李, 张自力. 侵袭性胸腺瘤与非侵袭性胸腺瘤的CT诊断与鉴别诊断[J]. 山西医药杂志(下半月刊), 2011, 40(11): 1105-1106.
|
[5]
|
李家贺, 向光宇, 张继朋, 等. 2023年第1版《NCCN胸腺瘤和胸腺癌临床实践指南》解读[J]. 中国胸心血管外科临床杂志, 2023, 30(4): 506-513.
|
[6]
|
Girard, N. (2019) Thymic Malignancies: Emerging Systemic Therapies. Current Opinion in Oncology, 31, 454-460.
https://doi.org/10.1097/CCO.0000000000000564
|
[7]
|
Funaki, S., Shintani, Y., Fukui, E., et al. (2020) Surgical Treatment Strategies for Invasive Thymoma. Journal of Thoracic Disease, 12, 7619-7625. https://doi.org/10.21037/jtd-19-3045
|
[8]
|
Wright, C.D. (2008) Management of Thymomas. Critical Reviews in Oncology/Hematology, 65, 109-120.
https://doi.org/10.1016/j.critrevonc.2007.04.005
|
[9]
|
Kondo, K. and Monden, Y. (2003) Therapy for Thymic Epi-thelial Tumors: A Clinical Study of 1,320 Patients from Japan. The Annals of Thoracic Surgery, 76, 878-884. https://doi.org/10.1016/S0003-4975(03)00555-1
|
[10]
|
Merveilleux du Vignaux, C., Dansin, E., Mhanna, L., et al. (2018) Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort. Journal of Thoracic Oncology, 13, 1762-1770.
https://doi.org/10.1016/j.jtho.2018.08.005
|
[11]
|
Rajan, A. and Giaccone, G. (2008) Treatment of Advanced Thy-moma and Thymic Carcinoma. Current Treatment Options in Oncology, 9, 277-287. https://doi.org/10.1007/s11864-009-0083-7
|
[12]
|
Wright, C.D., Choi, N.C., Wain, J.C., et al. (2008) Induction Chemoradiotherapy Followed by Resection for Locally Advanced Masaoka Stage III and IVA Thymic Tumors. The An-nals of Thoracic Surgery, 85, 385-389.
https://doi.org/10.1016/j.athoracsur.2007.08.051
|
[13]
|
Zhao, C. and Rajan, A. (2019) Immune Checkpoint Inhibitors for Treatment of Thymic Epithelial Tumors: How to Maximize Benefit and Optimize Risk? Mediastinum, 3, Article No. 35. https://doi.org/10.21037/med.2019.08.02
|
[14]
|
Herbst, R., Soria, J.-C., Kowanetz, M., et al. (2014) Predictive Correlates of Response to the Anti-PD-L1 Antibody MPDL3280A in Cancer Patients. Nature, 515, 563-567. https://doi.org/10.1038/nature14011
|
[15]
|
Garon, E.B., Rizvi, N.A., Hui, R., et al. (2015) Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. New England Journal of Medicine, 372, 2018-2028. https://doi.org/10.1056/NEJMoa1501824
|
[16]
|
Robert, C., Schachter, J., Long, G.V., et al. (2015) Pembrolizumab versus Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 372, 2521-2532. https://doi.org/10.1056/NEJMoa1503093
|
[17]
|
Weissferdt, A., Fujimoto, J., Kalhor, N., et al. (2017) Expression of PD-1 and PD-L1 in Thymic Epithelial Neoplasms. Modern Pathology, 30, 826-833. https://doi.org/10.1038/modpathol.2017.6
|
[18]
|
Padda, S.K., Riess, J.W., Schwartz, E.J., et al. (2015) Diffuse High Intensity PD-L1 Staining in Thymic Epithelial Tumors. Journal of Thoracic Oncology, 10, 500-508. https://doi.org/10.1097/JTO.0000000000000429
|
[19]
|
Giaccone, G., Kim, C., Thompson, J., et al. (2018) Pem-brolizumab in Patients with Thymic Carcinoma: A Single-Arm, Single-Centre, Phase 2 Study. The Lancet Oncology, 19, 347-355. https://doi.org/10.1016/S1470-2045(18)30062-7
|
[20]
|
Wei, S.C., Levine, J.H., Cogdill, A.P, et al. (2017) Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell, 170, 1120-1133. https://doi.org/10.1016/j.cell.2017.07.024
|
[21]
|
Walker, L.S. and Sansom, D.M. (2011) The Emerging Role of CTLA4 as A Cell-Extrinsic Regulator of T Cell Responses. Nature Reviews Immunology, 11, 852-863. https://doi.org/10.1038/nri3108
|
[22]
|
黄月雨, 余昶, 王佳慧, 等. 胸腺上皮肿瘤免疫检查点及免疫治疗研究进展[J]. 中国肿瘤, 2022, 31(7): 562-568.
|
[23]
|
He, Y., Ramesh, A., Gusev, Y., Bhuvaneshwar, K. and Giaccone, G. (2018) Molecular Predictors of Response to Pembrolizumab in Thymic Carcinoma. Cell Reports Medicine, 2, Article ID: 100392.
https://doi.org/10.1016/j.xcrm.2021.100392
|
[24]
|
Kwok, G., Yau, T.C., Chiu, J.W., Tse, E. and Kwong, Y.-L. (2016) Pembrolizumab (Keytruda). Human Vaccines & Immunotherapeutics, 12, 2777-2789. https://doi.org/10.1080/21645515.2016.1199310
|
[25]
|
Konstantina, T., Konstantinos, R., Anastasios, K., et al. (2019) Fatal Adverse Events in Two Thymoma Patients Treated with Anti-PD-1 Immune Check Point Inhibitor and Lit-erature Review. Lung Cancer, 135, 29-32.
https://doi.org/10.1016/j.lungcan.2019.06.015
|
[26]
|
Remon, J., Girard, N., Novello, S., et al. (2022) PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Len-vatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. Clinical Lung Cancer, 23, e243-e246. https://doi.org/10.1016/j.cllc.2021.07.008
|
[27]
|
Ak, N. and Aydiner, A. (2021) Nivolumab Treatment for Metastatic Thymic Epithelial Tumors. Journal of Oncology Pharmacy Practice, 27, 1710-1715. https://doi.org/10.1177/1078155220968150
|
[28]
|
Rajan, A., Heery, C.R., Thomas, A., et al. (2019) Efficacy and Tolerability of Anti-Programmed Death-Ligand 1 (PD-L1) Antibody (Avelumab) Treatment in Advanced Thymoma. Journal for ImmunoTherapy of Cancer, 7, Article No. 269.
https://doi.org/10.1186/s40425-019-0723-9
|
[29]
|
Kraehenbuehl, L., Weng, C.H., Eghbali, S., Wolchok, J.D. and Merghoub, T. (2022) Enhancing Immunotherapy in Cancer by Targeting Emerging Immunomodulatory Pathways. Na-ture Reviews Clinical Oncology, 19, 37-50.
https://doi.org/10.1038/s41571-021-00552-7
|